<DOC>
	<DOCNO>NCT01661621</DOCNO>
	<brief_summary>This study prospective randomize , open label , control , double arm , post-marketing study compare treatment efficacy first-line antimuscarinics α-blockers monotherapy men moderate severe low urinary tract symptom ( LUTS ) ( International Prostate Symptom Score ( IPSS-T ) ≥8 ) IPSS voiding-to-storage subscore ratio ( IPSS-V/S ) ≤1 .</brief_summary>
	<brief_title>Antimuscarinics First-line Treatment Male With IPSS-V/S≤1</brief_title>
	<detailed_description>1 . STUDY PROCEDURE 1.1.General Study Design This study prospective randomize , open label , control , double arm , post-marketing study compare treatment efficacy first-line antimuscarinics α-blockers monotherapy men moderate severe LUTS ( IPSS-T ≥8 ) IPSS-V/S ≤1 . 1.2 . Study Visits Evaluations 1.2.1 Screening Visit ( Baseline , 1 day 1 week first treatment day ) . 1.2.1.1 Explain nature study patient read sign Informed Consent Form . 1.2.1.2 Screen patient inclusion/exclusion criterion . 1.2.1.3 Medical History low urinary tract symptom previous treatment modality . 1.2.1.4 Vital sign monitoring , general physical examination system ( include digital rectal examination ) , serum prostatic specific antigen ( PSA ) , urinalysis . 1.2.1.5 Record Patient Perception Bladder Condition ( PPBC ) , IPSS ( IPSS-T , IPSS void ( IPSS-V ) , IPSS storage ( IPSS-S ) ) , Overactive Bladder Symptom Score ( OAB-SS ) , quality Life index ( QoL-I ) score . 1.2.1.6 Obtain maximum flow rate ( Qmax ) , voided volume , postvoid residual volume ( PVR ) , total prostate volume ( TPV ) , transitional zone index ( TZI ) . 1.2.1.7 Randomized assign patient 2 group ; men one group receive Doxazosin 4 mg QD , group receive Detrusitol 4 mg QD . 1.2.2 First Evaluation Visit ( 2 week initial treatment ) 1.2.2.1 Vital sign monitoring record adverse event . 1.2.2.2 Record PPBC , IPSS ( IPSS-T , IPSS-V , IPSS-S ) , OAB-SS QoL . 1.2.2.3 Check urinalysis urinary tract infection patient symptom suggestive urinary tract infection . 1.2.2.4 Check Qmax , void volume , PVR . 1.2.3 Second Evaluation Visit ( 4 week treatment ) . 1.2.3.1 Vital sign monitoring record adverse event . 1.2.3.3 Check urinalysis urinary tract infection patient symptom suggestive urinary tract infection . 1.2.3.4 Check Qmax , void volume , PVR . 1.2.4 Third Evaluation Visit ( 3 month treatment ) . 1.2.4.1 Vital sign monitoring record adverse event . 1.2.4.2 Record PPBC , IPSS ( IPSS-T , IPSS-V , IPSS-S ) , OAB-SS QoL . 1.2.4.3 Check urinalysis urinary tract infection patient symptom suggestive urinary tract infection . 1.2.4.4 Check Qmax , void volume , PVR . 1.3 . Withdrawal Criteria Patients follow condition may withdraw trial : 1.3.1 . Patients decide withdraw consent . 1.3.2 . Patients indicate status lack efficacy clinical significance judge investigator may lead permanent damage patient . 1.3.3 . Investigators consider safety concern patient remain trial ( development severe medical disease ) . 1.3.4 . Lost follow-up death . 1.3.5 . PVR≥300 mL 1.4 . Concomitant Treatments Investigator try minimize concomitant medication patient trial duration . However , patient allow continue take stable medication stable dose disease genitourinary system . 1.5 . Prohibited medication Patients allow take follow medication study : 1 . Anticholinergics test drug 2 . Alpha-adrenergic receptor blocker 3 . Tricyclic anti-depressants 4 . Calcium channel blocker 5 . Skeletal muscle relaxant 6 . Cyclooxygenase-2 ( COX-2 ) inhibitor</detailed_description>
	<mesh_term>Urinary Bladder Neck Obstruction</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Men age ≥40 year low urinary tract symptom ( IPSS ≥8 ) Patient his/her legally acceptable representative sign write informed consent form Patients severe cardiopulmonary disease congestive heart failure , arrhythmia , poorly control hypertension , able receive regular followup Patients urinary retention , urodynamically proven detrusor underactivity PVR ≥250 mL Patients know active urinary tract infection , urinary stone malignancy Patients history urethral injury transurethral surgery prostate bladder Patients laboratory abnormality screen include : 1 . Aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range 2 . Alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal range 3 . Patients abnormal serum creatinine level &gt; 2 x upper limit normal range Patients serious disease condition consider investigator suitable entry trial Patients participate investigational drug trial within 1 month enter study Patients major psychiatric illness drug abuse Patients take medication alphablocker , antimuscarinic 5 alphareductase ( 5AR ) inhibitor within 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Lower urinary tract symptom ( LUTS )</keyword>
	<keyword>International Prostate Symptom Score ( IPSS )</keyword>
	<keyword>Antimuscarinics</keyword>
	<keyword>α-blockers</keyword>
</DOC>